Eiger Bio scraps a mid-stage program after researchers record a clear flop in PAH, shares skid lower
Eiger BioPharmaceuticals $EIGR is scrapping one of its mid-stage programs for pulmonary arterial hypertension after their Phase II trial for ubenimex failed on several key fronts.
Researchers for Palo Alto, CA-based Eiger concluded that there was “no improvement overall or in key subgroups for both the primary efficacy endpoint of pulmonary vascular resistance and the secondary endpoint of 6-minute walk distance.” And now they’ll take a second look at the biomarkers while the company moves on with the rest of the programs they have in their rare disease pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
